BioNTech/OncoC4's Gotistobart Nearly Doubles Survival in Hard-to-Treat Lung Cancer Ahead of Pivotal Readout
- BioNTech and OncoC4 reported stage 1 overall-survival data from the phase 3 PRESERVE-003 trial in metastatic squamous NSCLC, ahead of the pivotal stage 2 readout.
- Gotistobart (BNT316/ONC-392) is a pH-sensitive anti-CTLA-4 antibody designed to selectively deplete regulatory T cells in the tumor microenvironment, a differentiated mechanism versus conventional CTLA-4 blockers like ipilimumab.
- In 87 randomized patients who had progressed on prior PD-(L)1 and platinum chemotherapy, median overall survival nearly doubled: 18.5 months with gotistobart versus 10.0 months with docetaxel (HR 0.56).
- Grade ≥3 treatment-related adverse events were similar between arms (44.4% vs 48.8%), with a manageable safety profile.
- Pivotal stage 2, with overall survival as the primary endpoint, is now underway at 160+ global sites.
The differentiator here is mechanism, not just efficacy: a pH-selective, tumor-restricted Treg-depletion approach delivering a near-doubling of OS over docetaxel with grade ≥3 toxicity roughly flat to chemo is the tolerability profile ipilimumab-based regimens have never cleared — that's the real competitive wedge against BMS's checkpoint franchise and every less-selective CTLA-4 follower. Eighty-seven patients and an HR of 0.56 is directional, not confirmatory, but it's a strong enough signal in a chemo-refractory population with no compelling 2L+ standard to justify running 160+ sites into stage 2 ahead of topline data. Bigger picture: this is BioNTech executing its post-COVID pivot — building a wholly-owned, mechanistically differentiated oncology franchise rather than leaning on mRNA vaccine partnerships. A pivotal win makes gotistobart the company's first major non-mRNA solid-tumor asset with real blockbuster optionality.
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout ↗